Compounding, Insurance and Magazine - Pharmacy Technician Pulse

Mapping the crisis: How data can help fix America’s growing pharmacy deserts

pharmaphorum

JUNE 12, 2025

These closures, compounded by the decline of independent pharmacies, create a critical gap in care. True visibility comes from layering pharmacy locations on top of geospatial data, such as population density, income levels, transportation access, insurance coverage, and health burden.

Health and Personal Care Stores

Health and Personal Care Stores Pharmaceutical Companies Pharmaceutical Companies Insurance Coverage

Juvenescence enhances AI drug discovery with Ro5 acquisition

Pharmaceutical Technology

JUNE 6, 2025

Ro5’s AI Chemistry Platform also uses advanced machine learning models and cheminformatics tools for quick compound discovery and design from hit identification to lead optimisation. Can pharma tariffs “Make America Manufacture Again”? Give your business an edge with our leading industry insights.

Communication

Communication Hospitals Packaging Compounding

J&J seeks FDA approval for icotrokinra to treat psoriasis

Pharmaceutical Technology

JULY 22, 2025

Find out more J&J holds exclusive worldwide rights to advance icotrokinra through Phase II clinical trials and beyond, as well as to commercialise any compounds resulting from the research for a wide array of indications. Give your business an edge with our leading industry insights.

FDA

FDA Immunization Packaging Communication

Hims & Hers shares plummet 35% as Novo Nordisk pulls partnership plug

Pharmaceutical Technology

JUNE 24, 2025

Robert Barrie June 24, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Compounded GLP-1RA medication has become a key revenue driver for Hims & Hers’ telehealth platform. Hims & Hers’ revenue has been soaring on the back of its compounded glucagon-like peptide-1 receptor agonist (GLP-1RA) sales.

Compounding

Compounding Packaging Communication FDA

Draig secures $140m for neuropsychiatric disorder therapies

Pharmaceutical Technology

JUNE 19, 2025

These compounds have the potential for addressing a spectrum of neuropsychiatric disorders that currently lack adequate treatment options. Can pharma tariffs “Make America Manufacture Again”? Give your business an edge with our leading industry insights.

Communication

Communication Hospitals Packaging Compounding

Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs

Pharmaceutical Technology

JUNE 12, 2025

Novo Nordisk is eyeing a cardiometabolic drug market future that is not purely dominated by incretins, after signing a $812m partnership with Deep Apple Therapeutics to access novel compounds for obesity and other diseases. Can pharma tariffs “Make America Manufacture Again”? Give your business an edge with our leading industry insights.

Compounding

Compounding Communication Hospitals Packaging

Novo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomes

Pharmaceutical Technology

JUNE 18, 2025

It recently initiated two more Phase III trials of its candidate CagriSema, as well as inking an $812m partnership with Deep Apple Therapeutics to access novel compounds, not GLP-1RAs, for obesity and other diseases. Can pharma tariffs “Make America Manufacture Again”? Give your business an edge with our leading industry insights.

Communication

Communication Hospitals Packaging Compounding

Vetter breaks ground on $285m US clinical manufacturing site

Pharmaceutical Technology

JUNE 30, 2025

The planned 160,000ft² facility will focus on aseptic production and includes areas for material preparation and compounding. June 30, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Bird’s-eye view of the current Vetter site in Des Plaines where the clinical manufacturing facility will be built.

Packaging

Packaging Compounding Hospitals Communication

AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal

Pharmaceutical Technology

JUNE 13, 2025

CSPC will use its AI-powered drug discovery platform, which uses the technology to analyse the binding patterns of target proteins with existing compound molecules. Can pharma tariffs “Make America Manufacture Again”? The AI models work out targeted optimisation, advancing small molecules with the best developability.

Communication

Communication Hospitals Vaccines Packaging

Why can’t the US figure out weight loss drug prices?

Pharmaceutical Technology

JUNE 27, 2025

Compounded GLP-1RAs have completely disrupted pricing frameworks for Wegovy and Mounjaro, what happens now? Price differences are especially pertinent with these weight loss drugs, which are officially called glucagon-like peptide-1 receptor agonists (GLP-1RA), due to the emergence of compounded alternatives in the past few years.

Compounding

Compounding Packaging FDA Communication

Novo Nordisk teams up with WeightWatchers in latest telehealth push

Pharmaceutical Technology

JUNE 27, 2025

In March 2025, Novo Nordisk discounted the cost of all doses to $499 per month to competitively price its prized asset against cheaper compounded alternatives. Compounded semaglutide is a personalised weight loss medicine, which is chemically identical to branded alternatives.

Compounding

Compounding Packaging FDA Communication

Myasthenia gravis market to reach $10.3bn across 7MM by 2034

Pharmaceutical Technology

JUNE 13, 2025

The myasthenia gravis (MG) market across the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the US) is poised to grow at a compound annual growth rate of 5.3% Can pharma tariffs “Make America Manufacture Again”? Credit: Vitalii Vodolazskyi via Shutterstock. billion in 2024 to $10.3

Communication

Communication Hospitals Vaccines Packaging

Pulmonary arterial hypertension market to reach $9.35bn across 7MM by 2034

Pharmaceutical Technology

JULY 8, 2025

The pulmonary arterial hypertension (PAH) market is forecast to grow at a compound annual growth rate (CAGR) of 2.0% Symptoms such as fatigue, breathlessness, and chest pain are frequently misattributed to more common conditions, delaying intervention and compounding disease burden. Credit: Green Apple via Shutterstock.

Packaging

Packaging Compounding Hospitals Communication

CTO East Coast 2025: Global oncology cell therapy market to hit $25bn by 2031

Pharmaceutical Technology

JULY 10, 2025

Ross Law July 10, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The global oncology market is set to grow at a compound annual growth rate (CAGR) of 24.5%. Image credit: CI Photos / Shutterstock. Give your business an edge with our leading industry insights.

Packaging

Packaging Compounding Hospitals Communication

Pharmacy Technician Pulse

Mapping the crisis: How data can help fix America’s growing pharmacy deserts

Juvenescence enhances AI drug discovery with Ro5 acquisition

Trending Sources

J&J seeks FDA approval for icotrokinra to treat psoriasis

Hims & Hers shares plummet 35% as Novo Nordisk pulls partnership plug

Draig secures $140m for neuropsychiatric disorder therapies

Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs

Novo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomes

Vetter breaks ground on $285m US clinical manufacturing site

AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal

Why can’t the US figure out weight loss drug prices?

Novo Nordisk teams up with WeightWatchers in latest telehealth push

Myasthenia gravis market to reach $10.3bn across 7MM by 2034

Pulmonary arterial hypertension market to reach $9.35bn across 7MM by 2034

CTO East Coast 2025: Global oncology cell therapy market to hit $25bn by 2031

Stay Connected